CareDx Stock Rockets 22% After Blowout Quarter and Big Guidance Hike, Extending a Nearly 500% One-Year Run
CareDx's stock surged 22% after Q3 results beat expectations, with revenue up 39% to $139.4M and adjusted earnings at 70 cents per share. The company raised its 2026 revenue guidance to $520M-$530M. Growth was driven by a 65% increase in testing services revenue, boosted by the Naveris acquisition. The stock closed at $87.41, with a market value of $4.6B.
How this was made
The 30-second read
Why it matters
This is a classic earnings-and-guidance repricing setup: the company delivered a large Q3 beat, drove growth via testing volumes, and raised full-year revenue and adjusted EBITDA targets, with additional support from clinical data presented at Kidney Week 2026.
Market read
Traders can act on a fresh, company-specific catalyst: raised full-year targets and a strong Q3 print that justify re-rating CDMO’s growth and margin outlook.
What to watch
The article flags reimbursement changes as a key risk and notes beta-driven volatility; traders may need to watch for post-rally profit-taking and guidance credibility versus consensus.
Background
CareDx is a transplant diagnostics company expanding beyond core transplant rejection monitoring into broader oncology testing after acquiring Naveris in July.
Market effects
Supports sentiment for transplant diagnostics and precision-medicine diagnostics, especially where testing volumes and reimbursement durability are key debate points.
Limited direct regional spillover; primarily a single-name repricing within US healthcare/diagnostics.
Modest, as the catalyst is company-specific clinical testing demand and guidance rather than a global macro or regulatory shift.
Counterpoint
The stock’s steep run may outpace fundamentals, and any reimbursement pressure or slower-than-expected integration of Naveris could quickly reverse the optimism.
Key entities
- companyCareDx
Transplant diagnostics company whose Q3 results and raised 2026 guidance drove a sharp share rally.
- companyNaveris
Maker of cancer blood tests acquired by CareDx in July, cited as a driver of testing-volume growth.
- conferenceAmerican Society of Nephrology (Kidney Week 2026)
Venue where CareDx presented multinational data on AlloSure Kidney and AlloSure Plus tests.
